Boehringer Ingelheim and Eli Lilly Present Results of Jardiance (empagliflozin) in P-III EMPEROR-Preserved Trial for the Treatment of HFpEF at ESC 2021
Shots:
- The P-III EMPEROR-Preserved trial evaluates the safety & efficacy of empagliflozin (10mg- qd) vs PBO in 5988 patients with chronic HFpEF
- The results demonstrated a 21% reduction in risk for composite 1EPs of CV death or hospitalization for HF. The 2EPs showed a 27% reduction in risk of first & recurrent hospitalizations for HF & slowed kidney function decline- safety data were consistent with previous findings with well-established safety profile of empagliflozin- results are published in the NEJM
- The companies plan for regulatory submissions globally in 2021. If approved- empagliflozin will be the 1st therapy across the HF spectrum
Ref: Businesswire | Image: Boehringer Ingelheim
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com